高级检索
当前位置: 首页 > 详情页

Association between cardiovascular risk factors and stage 1 hypertension defined by the 2017 ACC/AHA guidelines

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hangzhou Aeronaut Sanat Chinese Air Force, Convalescence Area 1, Hangzhou, Peoples R China [2]903 Hosp Peoples Liberat Army, Dept Cardiol, Hangzhou, Peoples R China [3]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Endocrinol, Sch Med, Shanghai, Peoples R China [4]Hangzhou Aeronaut Sanat Chinese Air Force, Management Dept, Hangzhou, Peoples R China
出处:
ISSN:

关键词: Hypertension cardiovascular disease dyslipidemia obesity hyperuricemia

摘要:
Background: A blood pressure (BP) of 130-139/80-89 mmHg has been defined as stage 1 hypertension by the 2017 American College of Cardiology/American Heart Association High Blood Pressure Clinical Practice Guidelines. This study was conducted to assess the association of cardiovascular risk factors (CRFs) and newly defined stage 1 hypertension in China. Methods: We analyzed the data of 84,489 adults with a BP of <140/90 mmHg. The 10-year cardiovascular disease (CVD) risk score was calculated using the China-PAR equation. Logistic analysis was used to assess the association between CRFs and stage 1 hypertension. Results: The mean values of CRFs, the proportion of metabolic abnormalities, the prevalence of >= 2 CRFs, and the 10-year CVD risk of individuals with a BP of 130-139/80-89 mmHg were significantly higher than those of the population with a BP of <130/80 mmHg. The adjusted odds ratios (ORs) of waist circumference, fasting plasma glucose (FPG), and triglycerides were 1.362 (CI 95% = 1.081-1.715, p = .009), 1.264 (CI 95% = 1.093-1.462, p = .002), and 1.331 (CI 95% = 1.009-1.755, p = .043), respectively. Other CRFs were not significantly associated with stage 1 hypertension. Conclusions: Multidisciplinary and targeted interventions are required to manage the CRFs (especially abdominal obesity, elevated FPG, and hypertriglyceridemia) of the population with a BP of 130-139/80-89 mmHg in China.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 外周血管病 4 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 外周血管病 4 区 药学
JCR分区:
出版当年[2018]版:
Q4 PHARMACOLOGY & PHARMACY Q4 PERIPHERAL VASCULAR DISEASE
最新[2023]版:
Q3 PERIPHERAL VASCULAR DISEASE Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Hangzhou Aeronaut Sanat Chinese Air Force, Convalescence Area 1, Hangzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [4]Hangzhou Aeronaut Sanat Chinese Air Force, Management Dept, Hangzhou, Peoples R China [*1]Hangzhou Aeronaut Sanat Chinese Air Force, 27 Yang Gong Di, Hangzhou 310007, Zhejiang, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)